NSCs are permissive to oncolytic Myxoma virus and provide a delivery method for targeted ovarian cancer therapy

Despite the development of many anticancer agents over the past 20 years, ovarian cancer remains the most lethal gynecologic malignancy. Due to a lack of effective screening, the majority of patients with ovarian cancer are diagnosed at an advanced stage, and only ~20% of patients are cured. Thus, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornejo, Yvonne, Li, Min, Dellinger, Thanh H., Mooney, Rachael, Rahman, Masmudur M., McFadden, Grant, Aboody, Karen S., Hammad, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771716/
https://www.ncbi.nlm.nih.gov/pubmed/33473255
http://dx.doi.org/10.18632/oncotarget.27845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771716/
https://www.ncbi.nlm.nih.gov/pubmed/33473255
http://dx.doi.org/10.18632/oncotarget.27845

Ejemplares similares